Your browser doesn't support javascript.
loading
Evaluating the impact of efpeglenatide on cardiometabolic and safety outcomes in individuals with diabetes: a systematic review and meta-analysis.
Qazi, Shurjeel Uddin; Ansari, Huzaifa Ul Haq; Tharwani, Zoaib Habib; Altaf, Zahabia; Noman, Ayesha; Ghazanfar, Shamas; Kumar, Sangeet; Ansari, Haya Waseem; Nasir, Muhammad Moiz; Qazi, Sana.
Afiliación
  • Qazi SU; Dow University of Health Sciences, Karachi, Pakistan.
  • Ansari HUH; Liaquat National Hospital, Karachi, Pakistan.
  • Tharwani ZH; Dow University of Health Sciences, Karachi, Pakistan.
  • Altaf Z; Dow University of Health Sciences, Karachi, Pakistan.
  • Noman A; Dow University of Health Sciences, Karachi, Pakistan.
  • Ghazanfar S; Dow University of Health Sciences, Karachi, Pakistan.
  • Kumar S; Dow University of Health Sciences, Karachi, Pakistan.
  • Ansari HW; Royal Institute of Medicine and Surgery Trauma Hospital, Karachi, Pakistan.
  • Nasir MM; Liaquat National Hospital, Karachi, Pakistan.
  • Qazi S; Dow University of Health Sciences, Karachi, Pakistan.
J Diabetes Metab Disord ; 23(1): 405-415, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38932865
ABSTRACT

Background:

Efpeglenatide, a novel GLP-1 receptor agonist, has shown promise in improving glycemic control and inducing weight loss in individuals with type 2 diabetes (T2DM). This meta-analysis assessed its therapeutic potential and safety profile.

Methods:

A literature search was conducted on PubMed, SCOPUS, and Cochrane Central from inception until September 2023. We selected patients with T2DM and identified and compared those receiving efpeglenatide to placebo. Outcomes assessed included fasting plasma glucose (FPG), HbA1c, body weight, BMI, and cardiometabolic parameters. Data were analyzed using a random-effects model, with results presented as mean differences (MD) for continuous outcomes and risk ratios (RR) for safety analysis, along with their respective 95% confidence intervals. Quality assessment was conducted using the Cochrane risk of bias tool.

Results:

We included 11 studies in our analysis. Efpeglenatide demonstrated significant reductions in FPG (MD = -1.53 mmol/L, 95% CI = [-2.86, -0.66], p < 0.01), HbA1c (MD = -0.84, 95% CI= [-1.08, -0.60], p < 0.01), body weight (MD = -2.24 kg, 95% CI = [-4.20, -2.00], p < 0.01), and BMI (MD = -1.61 kg/m2, 95% CI= [-2.12, -1.09], p < 0.01). However, efpeglenatide was associated with a moderate increase in the risk of gastrointestinal adverse events, nausea, diarrhea, and vomiting. There was a non-significant elevated risk of hypoglycemia.

Conclusions:

Efpeglenatide significantly improves glycemic outcomes and promotes weight loss in individuals with diabetes. However, it is associated with moderate adverse effects related to the gastrointestinal system. Thus, further trials are warranted to comprehensively assess its safety and efficacy to derive a robust conclusion. Supplementary Information The online version contains supplementary material available at 10.1007/s40200-024-01409-3.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Diabetes Metab Disord Año: 2024 Tipo del documento: Article País de afiliación: Pakistán Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Diabetes Metab Disord Año: 2024 Tipo del documento: Article País de afiliación: Pakistán Pais de publicación: Suiza